“Our vaccine is more cost-effective and it identifies particular proteins of the virus that create resistance, instead of inducing the virus into the body to create immunity,” said a researcher at RMRIMS.
The facility’s research manuscript, ‘A First Step towards Vaccine Development’ has been sent for publication in Elsevier’s international journal, ‘Infection, Genetics and Evolution’.
According to researchers, they used the online database of proteins made available by US-funded National Centre for Biotechnology Information to identify fragments of the proteins, called peptides, which could be combined with human cells to create immunity against the virus.
“The process of identifying these peptides to create immunity is called conservancy. The higher the conservancy, greater the chances of creating a vaccine. We have identified proteins with 100% conservancy,” researchers said.